Posted by Michael Wonder on 10 Jul 2023
US FDA approves expanded indication for Novartis Leqvio (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease
10 July 2023 - Expanded indication now enables broader use of Leqvio for LDL-C reduction in patients with primary hyperlipidaemia (high LDL-C).
Novartis announced today that the US FDA has approved a label update for Leqvio (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy.
